CTI BioPharma Corp. (CTIC) Announces Earnings Results
CTI BioPharma Corp. (NASDAQ:CTIC) issued its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04, Bloomberg Earnings reports. CTI BioPharma Corp. had a negative return on equity of 418.99% and a negative net margin of 136.76%. The company had revenue of $1.71 million during the quarter, compared to analysts’ expectations of $0.30 million.
Shares of CTI BioPharma Corp. (NASDAQ CTIC) traded down $0.03 during mid-day trading on Tuesday, hitting $3.02. The company had a trading volume of 152,092 shares, compared to its average volume of 147,546. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.15 and a quick ratio of 2.11. CTI BioPharma Corp. has a fifty-two week low of $2.70 and a fifty-two week high of $6.48.
In other CTI BioPharma Corp. news, Director Richard L. Love sold 14,600 shares of the company’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $3.21, for a total transaction of $46,866.00. Following the completion of the sale, the director now directly owns 84,318 shares in the company, valued at $270,660.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.08% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “CTI BioPharma Corp. (CTIC) Announces Earnings Results” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/11/07/cti-biopharma-corp-ctic-announces-earnings-results.html.
A number of brokerages have recently issued reports on CTIC. Jefferies Group LLC initiated coverage on CTI BioPharma Corp. in a report on Tuesday, September 12th. They set a “buy” rating and a $7.50 price objective for the company. ValuEngine cut CTI BioPharma Corp. from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 11th.
About CTI BioPharma Corp.
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Stock Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related stocks with our FREE daily email newsletter.